ClinicalTrials.gg
WithdrawnNCT01104844Updated Jul 12, 2013

Maxi-Analgesic Phase 2 Study to Compare the Analgesic Effects in Different Dosing Groups to Treat Teeth Extraction Pain

A Phase 2 interventional study of Full Dose Strength and Quarter dose strength in Dental Pain, sponsored by AFT Pharmaceuticals, Ltd.. Withdrawn at 1 site in United States. Open to participants aged 16 Years to 40 Years. Per ClinicalTrials.gov, last updated 2013-07-12.

Sponsored by AFT Pharmaceuticals, Ltd. · Phase 2, Interventional, and Treatment

Why this study was withdrawn
The study was withdrawn due to administrative reason

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
16 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 55 studies in Toothache with a site in United States — 7 open to participants now, 7 under way, none of them phase 3. Toothache · United States.

Enrollment
50th of 51
0 · median 193
Phase 2
21 of 55
1 open now
Registered
18th of 55
by date
Lead sponsor
2 of 55
AFT Pharmaceuticals, Ltd.

Among the 55 studies in Toothache with a site in United States, this one is the 50th largest by enrollment of the 51 interventional ones that give a count, is one of 21 in phase 2, and was the 18th registered.

Toothache

142 studies on the registry are indexed under Toothache; 28 are open to participants now.

Browse Toothache studies →

Open to participants now

7 of the 55 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 16 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Toothache with a site in United States, or all of them as a file.
02

Study summary

The aim of the study is to examine the dose response relationship in the treatment of dental pain (teeth extraction) for the different potential doses of the investigational drug, i.e. 2 tablets, 1 tablet or ½ a tablet given 4 times a day.

Read the detailed description

The combination of 500 mg acetaminophen and 150 mg ibuprofen has been shown to improve analgesia compared with the individual components, when given as 2 tablets (i.e., total of 1,000/300 mg) 4 times a day for dental pain.

The analgesic relief from 2 tablets of the combination was around 6 hours, and so consistent with 4 times a day dosing.

The combination tablets are scored to allow for lower doses and can be given as 2 tablets (total of 1,000/300 mg), 1 tablet (500/150 mg) or ½ tablet (250/75 mg) in multiple doses.

However different dose response combinations need to be investigated to confirm the dose response curve of the combination and to compare the relative efficacy with acetaminophen and different doses of ibuprofen (lower and higher dose).

The study hypothesis is the analgesic response to three different combination doses, the three single component doses 500mg acetaminophen and 150mg and 300mg ibuprofen, and placebo administered four times daily over 24 hours for post-operative dental pain will form a representative dose response curve.

The study design is multi-centre, prospective, placebo-controlled, randomized, double-blind, factorial parallel group.

Participants will be stratified for baseline pain at inclusion (moderate or severe pain based a 4 point pain intensity rating scale).

Recruitment will continue until there are at least 350 participants in the ITT population.

Efficacy: The primary efficacy objective is to compare the time-adjusted SPIDs (Summed Pain Intensity Differences) of the VAS pain intensity scores up to 24 hours after the first dose of study medication among the 7 treatment groups to determine the form of the dose-response relationship.

Secondary efficacy objectives are:

  • To compare the maximum VAS pain scores for the 24-hour period after the first dose of study medication among the seven treatment groups to determine the form of the dose response relationship.
  • To compare the response rates (response rate to be defined as the percentage of participants who achieve at least 50% reduction in baseline pain within 6 hours i.e. the first dose period) among the seven treatment groups to determine the form of the dose response relationship.
  • To determine and compare the time to peak reduction in VAS pain intensity scores following the first dose of study medication among the seven treatment groups to determine the form of the dose response relationship.
  • To compare time to perceptible and meaningful pain relief among the seven treatment groups using the two stopwatch method.
  • To compare the time to requirement for rescue medication among the seven treatment groups.
  • To compare the amount of rescue medication used (defined as the number of tablets) among the seven treatment groups over the 24-hour treatment period.
  • To compare the percentage of participants requiring rescue medication among the seven treatment groups.
  • To compare the categorical global pain rating among the seven treatment groups.

Safety:

To compare adverse event rates (divided into serious and non-serious adverse events). Adverse events will be assessed for the 24- hour study period and up to 30 days after the final dose of study medication among the seven treatment groups.

The standard symptoms expected in subjects who have recently undergone third molar extraction will not be recorded as AEs in this study, unless they are of greater severity and/or intensity than would be expected. The events considered to be standard for the purposes of this study are:

  • Oral pain.
  • Facial swelling.
  • Oral bleeding.
  • Bruising to face, neck, and/or jaw.
  • Decreased range of motion of the jaw.
  • Dry socket.

The Investigators will use their clinical judgement in determining whether these symptoms are of greater severity and/or intensity than would be expected.

Planned hospital admissions and/or surgical operations for an illness or disease which existed before the drug was given or the participant was randomized in a clinical study will not be considered adverse events The incidence of known specific NSAID and acetaminophen side effects (e.g. GI ulceration, Indigestion/stomach pain, post-operative bleeding, thromboembolic events and evidence of clinical hepatitis) during the 24-hour study period and up to 30 days after the last dose will be compared among the seven treatments.

03

Conditions studied

  • Dental Pain

Browse trials for

Keywords

  • dental pain
  • Analgesia
04

Who can participate

Ages eligible
16 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written before initiation of any study-related procedures.
  2. Males and females aged at least 16 years and not more than 40 years old on the day of consent.
  3. Undergoing oral surgery for the extraction of 2 impacted 3rd molar teeth, one of which must be mandibular and require bone removal.
  4. Experiencing moderate to severe post-operative pain, as defined by a 4 point categorical pain intensity rating scale with 0 = no pain; 1 = mild pain; 2 = moderate pain and 3 = severe pain(at rest) within 6 hours after completion of surgery.
  5. Baseline VAS pain intensity score of > 50mm on a 100mm VAS scale with 0 = no pain and 100 = worst pain imaginable.

Exclusion criteria

Exclusion Criteria:

Study :

  1. Has taken any NSAID or acetaminophen within 12 hours prior to the start of surgery other than aspirin ≤ 150mg/day.
  2. Subjects who have received any anesthetics from midnight the night prior to surgery, except for lidocaine with epinephrine, nitrous oxide, diazepam (Valium®), methohexital (Brevital®).
  3. Known to be pregnant or possibly pregnant.
  4. Women of who are unwilling to take adequate precautions, i.e., a hormonal contraceptive, an intrauterine device, double-barrier method, or abstinence (should the subject become sexually active, she must agree to use a double-barrier method of contraception). A woman of childbearing potential is defined as any female who is less than 2 years or has not undergone a partial or total hysterectomy or surgical sterilization, e.g., bilateral tubal ligation, bilateral oophorectomy.
  5. Suffering from a neurological disorder relating to pain perception or any acute or chronic condition that, in the opinion of the investigator, makes the subject unsuitable from an efficacy or safety perspective.
  6. In the opinion of the investigator, unable to understand the visual analogue pain score or comply with the protocol requirements.
  7. Currently or in last 30 days, has been in a clinical trial involving another study drug.
  8. Currently treated with an ACE inhibitor, warfarin, (other than nasal steroids or topical steroids with the approval of the investigator), cyclosporin, tacrolimus or methotrexate, or any other medication felt by the investigator to interfere with safety or efficacy evaluations.
  9. Participant weight \< 50kg.Suffering from any other diseases or condition which, in the opinion of the investigator, means that it would not be in the participant's best interests to participate in this study.

    NSAID and/or acetaminophen contra-indications:

  10. to aspirin or other NSAID.
  11. Hypersensitivity to acetaminophen.
  12. Severe known hemopoietic, renal or hepatic disease, or .
  13. History of gastric ulceration or other GI disorders that, in the opinion of the investigator make the subject unsuitable (e.g., frequent treatment of GERD, inflammatory bowel disease, etc.).
  14. History of severe asthma defined as asthma requiring frequent or ongoing treatment to control symptoms. Exercise-induced asthma or mild asthma not requiring ongoing treatment may not be exclusionary at the discretion of the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Half dose strength

    Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg), i.e 2 tablets equating to ½ the dose in the standard investigational drug

    Drug: Half dose strength

  • Active comparator
    Quarter dose strength

    Investigational drug quarter dose strength (acetaminophen125mg + Ibuprofen 37.5mg) i.e. 2 tablets equating to ¼ the dose in the standard investigational drug.

    Drug: Quarter dose strength

  • Active comparator
    Acetaminophen standard dose

    Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug

    Drug: Acetaminophen standard dose

  • Active comparator
    ibuprofen low dose

    Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product

    Drug: Ibuprofen low dose

  • Active comparator
    Ibuprofen high dose

    Ibuprofen High dose 300mg i.e. 2 tablets equating to twice the ibuprofen dose as in the standard investigational drug

    Drug: Ibuprofen high dose

  • Placebo comparator
    placebo

    2 Placebo tablets

    Drug: Placebo

  • Experimental
    Full Dose Strength

    Investigational drug full dose strength (acetaminophen 500mg + ibuprofen 150mg) i.e. 2 tablets

    Drug: Full Dose Strength

Interventions

  • DrugFull Dose Strength

    Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)

    Also known as: Brand name Maxigesic

  • DrugQuarter dose strength

    Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.

    Also known as: Maxigesic Quarter Dose

  • DrugHalf dose strength

    Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug

    Also known as: Maxigesic half dose

  • Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug

    Also known as: paracetamol

  • Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product

    Also known as: Ibuprofen

  • Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug

    Also known as: Ibuprofen

  • DrugPlacebo

    2 placebo tablets

06

What researchers measure

Primary outcomes

  1. the time-adjusted SPIDs of the VAS pain intensity scores

    The primary efficacy objective is to compare the time-adjusted SPIDs of the VAS pain intensity scores up to 24 hours after the first dose of study medication among the 7 treatment groups to determine the form of the dose-response relationship.

    Time frame: 24 hours after the first dose

Secondary outcomes

  1. the maximum VAS pain score

    To compare the maximum VAS pain scores for the 24-hour period after the first dose of study medication among the seven treatment groups to determine the form of the dose response relationship.

    Time frame: 24 hours after the first dose

  2. The Response Rate

    To compare the response rates (response rate to be defined as the percentage of participants who achieve at least 50% reduction in baseline pain within 6 hours i.e. the first dose period) among the seven treatment groups to determine the form of the dose response relationship.

    Time frame: 24 hours after the first dose

  3. The time to peak reduction in VAS pain intensity scores

    To determine and compare the time to peak reduction in VAS pain intensity scores following the first dose of study medication among the seven treatment groups to determine the form of the dose response relationship.

    Time frame: 24 hours after the first dose

  4. The time to perceptible and meaningful pain relief

    To compare time to perceptible and meaningful pain relief among the seven treatment groups using the two stopwatch method.

    Time frame: 24 hours after the first dose

  5. The time to requirement for rescue medication

    To compare the time to requirement for rescue medication among the seven treatment groups.

    Time frame: 24 hours after the first dose

  6. The amount of rescue medication used

    To compare the amount of rescue medication used (defined as the number of tablets) among the seven treatment groups over the 24-hour treatment period.

    Time frame: 24 hours after the first dose

  7. The percentage of participants requiring rescue medication

    To compare the percentage of participants requiring rescue medication among the seven treatment groups.

    Time frame: 24 hours after the first dose

  8. The categorical global pain rating

    To compare the categorical global pain rating among the seven treatment groups which is obtained at the end of 24 hours study period.

    Time frame: 24 hours after the first dose

  9. The incidence of adverse events

    Adverse events (divided into serious and non-serious adverse events) will be assessed for the study period. Adverse events will also be determined up to 30 days after the last dose. The incidence of individual specific NSAID and acetaminophen side effects (e.g. GI ulceration, indigestion/stomach pain, post-operative bleeding and evidence of clinical hepatitis) will be determined up to 30 days after the last dose.

    Time frame: up to 30 days after the last dose

07

Study locations

1 site
  • Austin Clinic
    Austin, Texas 78705, United States
08

References and documents

Publications

  • Merry AF, Gibbs RD, Edwards J, Ting GS, Frampton C, Davies E, Anderson BJ. Combined acetaminophen and ibuprofen for pain relief after oral surgery in adults: a randomized controlled trial. Br J Anaesth. 2010 Jan;104(1):80-8. doi: 10.1093/bja/aep338. PubMed 20007794 ↗
  • Ong CK, Seymour RA, Lirk P, Merry AF. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg. 2010 Apr 1;110(4):1170-9. doi: 10.1213/ANE.0b013e3181cf9281. Epub 2010 Feb 8. PubMed 20142348 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01104844
Lead sponsor
AFT Pharmaceuticals, Ltd.
Responsible party
Sponsor
First posted
Apr 16, 2010
Last update
Jul 12, 2013

Study contacts

Michael Kuss, Doctor
principal investigator · Premier Research Group Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion